COPD – eine unterschätzte Erkrankung [COPD - An Underestimated Disease]
Détails
Télécharger: 37282526 .pdf (380.95 [Ko])
Etat: Public
Version: Final published version
Licence: CC BY 4.0
Etat: Public
Version: Final published version
Licence: CC BY 4.0
ID Serval
serval:BIB_F7EFDA383D97
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
COPD – eine unterschätzte Erkrankung [COPD - An Underestimated Disease]
Périodique
Praxis
ISSN
1661-8157 (Print)
ISSN-L
1661-8157
Statut éditorial
Publié
Date de publication
06/2023
Peer-reviewed
Oui
Volume
112
Numéro
7-8
Pages
403-412
Langue
allemand
Notes
Publication types: English Abstract ; Journal Article
Publication Status: ppublish
Publication Status: ppublish
Résumé
COPD - An Underestimated Disease Abstract: Chronic obstructive pulmonary disease (COPD) is a heterogeneous lung condition with a complex clinical picture. The diagnosis is not easy to make because COPD can develop insidiously and remain unnoticed for a long time. Therefore, general practitioners play a central role in the early detection of the disease. Suspected COPD can be confirmed by special examinations in collaboration with pulmonologists. The new GOLD guideline defines three COPD risk groups (A-B-E) which should guide the personalized treatment concept. A short- or long-acting bronchodilator (SAMA/SABA or LAMA/LABA) is recommended for group A, and a dual long-acting bronchodilator therapy (LABA+LAMA) is recommended for group B and E. In case of blood eosinophilia (≥300 cells/µl) and/or recent hospitalization for COPD exacerbation, triple therapy (LABA+LAMA+ICS) is recommended. General practitioners are important in implementing non-pharmacological measures (smoking cessation, regular exercise, vaccinations, patient selfmanagement education). However, this also underlines the high demands of the implementation of the GOLD guideline in daily practice.
Mots-clé
Humans, Bronchodilator Agents/therapeutic use, Drug Therapy, Combination, Pulmonary Disease, Chronic Obstructive/therapy, Pulmonary Disease, Chronic Obstructive/drug therapy, Administration, Inhalation, Adrenergic beta-2 Receptor Agonists/therapeutic use, Adrenal Cortex Hormones/therapeutic use, BPCO, COPD, COPD management, COPD-Management, GOLD Guideline, GOLD guideline, GOLD-Guideline, Hausärztin/Hausarzt, Therapiekonzept, concept thérapeutique, general practitioner, médecin de premier recours, prise en charge de la BPCO, therapeutic concept
Pubmed
Open Access
Oui
Création de la notice
14/06/2023 8:53
Dernière modification de la notice
10/02/2024 7:30